Cargando…
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response
Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but our understanding of the requirements for a robust ICB response is incomplet...
Autores principales: | Ibáñez-Molero, Sofía, van Vliet, Alex, Pozniak, Joanna, Hummelink, Karlijn, Terry, Alexandra M., Monkhorst, Kim, Sanders, Joyce, Hofland, Ingrid, Landeloos, Ewout, Van Herck, Yannick, Bechter, Oliver, Kuilman, Thomas, Zhong, Weiwei, Marine, Jean-Christophe, Wessels, Lodewyk, Peeper, Daniel S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710519/ https://www.ncbi.nlm.nih.gov/pubmed/36465485 http://dx.doi.org/10.1080/2162402X.2022.2139074 |
Ejemplares similares
-
Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer
por: Celus, Ward, et al.
Publicado: (2022) -
Phenotypic diversity drives paracrine drug tolerance
por: Kuilman, Thomas, et al.
Publicado: (2017) -
Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival
por: Iskit, Sedef, et al.
Publicado: (2015) -
Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy
por: Riaz, Nadeem, et al.
Publicado: (2016) -
IgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease
por: Biasiolo, Alessandra, et al.
Publicado: (2012)